巨细胞动脉炎易感性相关风险位点:一项全基因组关联研究
该研究汇集欧洲和北美十个队列的基因组数据进行荟萃分析,纳入3498例巨细胞动脉炎患者和15550例健康对照,鉴定出MFGE8、VTN和CCDC25三个新风险位点,并发现HLA区域和PLG关联,多基因风险评分在90百分位OR为2.87。
要点
- 新发现MFGE8、VTN和CCDC25三个与巨细胞动脉炎风险相关的位点。
- MFGE8和VTN与血管生成通路相关,CCDC25与中性粒细胞胞外诱捕网相关。
- 多基因风险评分90百分位OR 2.87(95%CI 2.15-3.82)可识别高风险个体。
核心结论
- 研究发现多个与巨细胞动脉炎相关的位点,凸显血管生成在疾病易感性中的关键作用。
- 研究提出新的治疗候选药物和衡量遗传易感性的方法,向临床转化迈进一步。
研究设计与样本
- 研究收集并荟萃分析了来自欧洲和北美十个队列的巨细胞动脉炎患者与健康对照的基因组数据,均为欧洲血统。
- 患者入组要求经颞动脉活检阳性、颞动脉多普勒超声阳性或影像学证实大血管炎来确认巨细胞动脉炎诊断。
- 研究采用细胞富集分析、精细定位和因果基因优先级排序评估相关位点的功能后果,并进行药物重定位分析和多基因风险评分。
主要发现
- 共纳入3498例巨细胞动脉炎患者和15550例对照。
- MFGE8位点rs8029053与巨细胞动脉炎风险相关(p=4.96×10⁻⁸;OR 1.19,95%CI 1.12-1.26)。
- VTN位点rs704与巨细胞动脉炎风险相关(p=2.75×10⁻⁹;OR 0.84,95%CI 0.79-0.89)。
- CCDC25位点rs11782624与巨细胞动脉炎风险相关(p=1.28×10⁻⁸;OR 1.18,95%CI 1.12-1.25)。
- 多基因风险评分模型在90百分位识别巨细胞动脉炎风险增加个体(OR 2.87,95%CI 2.15-3.82;p=1.73×10⁻¹³)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Giant cell arteritis is an age-related vasculitis that mainly affects the aorta and its branches in individuals aged 50 years and older. Current options for diagnosis and treatment are scarce, highlighting the need to better understand its underlying pathogenesis. Genome-wide association studies (GWAS) have emerged as a powerful tool for unravelling the pathogenic mechanisms involved in complex diseases. We aimed to characterise the genetic basis of giant cell arteritis by performing the largest GWAS of this vasculitis to date and to assess the functional consequences and clinical implications of identified risk loci. METHODS: We collected and meta-analysed genomic data from patients with giant cell arteritis and healthy controls of European ancestry from ten cohorts across Europe and North America. Eligible patients required confirmation of giant cell arteritis diagnosis by positive temporal artery biopsy, positive temporal artery doppler ultrasonography, or imaging techniques confirming large-vessel vasculitis. We assessed the functional consequences of loci associated with giant cell arteritis using cell enrichment analysis, fine-mapping, and causal gene prioritisation. We also performed a drug repurposing analysis and developed a polygenic risk score to explore the clinical implications of our findings. FINDINGS: We included a total of 3498 patients with giant cell arteritis and 15 550 controls. We identified three novel loci associated with risk of giant cell arteritis. Two loci, MFGE8 (rs8029053; p=4·96 × 10-8; OR 1·19 [95% CI 1·12-1·26]) and VTN (rs704; p=2·75 × 10-9; OR 0·84 [0·79-0·89]), were related to angiogenesis pathways and the third locus, CCDC25 (rs11782624; p=1·28 × 10-8; OR 1·18 [1·12-1·25]), was related to neutrophil extracellular traps (NETs). We also found an association between this vasculitis and HLA region and PLG. Variants associated with giant cell arteritis seemed to fulfil a specific regulatory role in crucial immune cell types. Furthermore, we identified several drugs that could represent promising candidates for treatment of this disease. The polygenic risk score model was able to identify individuals at increased risk of developing giant cell arteritis (90th percentile OR 2·87 [95% CI 2·15-3·82]; p=1·73 × 10-13). INTERPRETATION: We have found several additional loci associated with giant cell arteritis, highlighting the crucial role of angiogenesis in disease susceptibility. Our study represents a step forward in the translation of genomic findings to clinical practice in giant cell arteritis, proposing new treatments and a method to measure genetic predisposition to this vasculitis. FUNDING: Institute of Health Carlos III, Spanish Ministry of Science and Innovation, UK Medical Research Council, and National Institute for Health and Care Research.
引用
- Borrego-Yaniz G, Ortiz-Fernández L, Madrid-Paredes A, et al. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study. Lancet Rheumatol. 2024. PMID: 38734017. doi:10.1016/S2665-9913(24)00064-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。